New hope for kidney patients: experimental drug targets protein leak

NCT ID NCT05267262

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called R3R01 in 43 people with two rare kidney diseases (Alport syndrome and focal segmental glomerulosclerosis) whose protein in urine remained high despite standard treatment. The main goals were to check safety and see if the drug could reduce protein leakage from the kidneys. Results will help decide if larger studies are warranted.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alport syndrome focal segmental glomerulosclerosis hereditary nephritis kidney disorder primary focal segmental glomerulosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigative Site

    Los Angeles, California, 90022, United States

  • Investigative Site

    Cary, North Carolina, 27511, United States

  • Investigative Site

    Dallas, Texas, 75204, United States

  • Investigative site

    Boca Raton, Florida, 33431, United States

  • Investigative site

    Miami, Florida, 33136, United States

  • Investigative site

    Riverview, Florida, 33578, United States

  • Investigative site

    Atlanta, Georgia, 30322, United States

  • Investigative site

    Boston, Massachusetts, 02111, United States

  • Investigative site

    Ann Arbor, Michigan, 48109-5718, United States

  • Investigative site

    Minneapolis, Minnesota, 55454, United States

  • Investigative site

    Cleveland, Ohio, 44195, United States

  • Investigative site

    Columbus, Ohio, 43235, United States

  • Investigative site

    East Providence, Rhode Island, 02914, United States

  • Investigative site

    Houston, Texas, 77054, United States

  • Investigative site

    Brussels, 1200, Belgium

  • Investigative site

    Liège, 4000, Belgium

  • Investigative site

    Paris, 75015, France

  • Investigative site

    Göttingen, 37075, Germany

  • Investigative site

    Amsterdam, 1105AZ, Netherlands

  • Investigative site

    Nijmegen, 6525 GA, Netherlands

  • Investigative site

    Leicester, LE5 4PW, United Kingdom

  • Investigative site

    Nottingham, NG5 1PB, United Kingdom